KalVista Pharmaceuticals

KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline resulting from over 20 years of leading pharmaceutical discovery in the field of serine protease inhibitors and is targeting both intravitreal injection and oral administration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.

KalVista Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Diabetes sector. The company focuses on Biotechnology and has secured $27.5B in funding across 60 round(s). With a team of 101-250 employees, KalVista Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - KalVista Pharmaceuticals, raised $13.2M. Discover more about their projects, partnerships, and impact on our platform.